Eyepoint Pharmaceuticals

Yahoo Finance • 14 days ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, t... Full story

Yahoo Finance • last month

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 2 months ago

National Vision stock price target raised to $33 at Jefferies

Investing.com - Jefferies raised its price target on National Vision Holdings (NASDAQ:EYE) to $33.00 from $22.00 on Monday, while maintaining a Buy rating on the stock. The company, currently trading at $22.64 with a market capitalizatio... Full story

Yahoo Finance • 2 months ago

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market

EYEPOINT PHARMACEUTICALS INC (NASDAQ:EYPT [https://www.chartmill.com/stock/quote/EYPT/profile]) REPORTS Q2 2025 EARNINGS: MISSES ESTIMATES AS MARKET REACTS NEGATIVELY EyePoint Pharmaceuticals Inc. released its second-quarter 2025 financia... Full story

Yahoo Finance • 2 months ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 2 months ago

EyePoint Pharmaceuticals GAAP EPS of -$0.85 misses by $0.04, revenue of $5.3M misses by $0.86M

* EyePoint Pharmaceuticals press release [https://seekingalpha.com/pr/20190701-eyepoint-reports-second-quarter-2025-financial-results-and-highlights-recent-corporate] (NASDAQ:EYPT [https://seekingalpha.com/symbol/EYPT]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 2 months ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-wee... Full story

Yahoo Finance • 2 months ago

EyePoint Pharmaceuticals Q2 2025 Earnings Preview

* EyePoint Pharmaceuticals (NASDAQ:EYPT [https://seekingalpha.com/symbol/EYPT]) is scheduled to announce Q2 earnings results on Wednesday, August 6th, before market open. * The consensus EPS Estimate is -$0.80 [https://seekingalpha.com... Full story

Yahoo Finance • 2 months ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 2 months ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across t... Full story

Yahoo Finance • 5 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, tod... Full story

Yahoo Finance • 6 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal disea... Full story

Yahoo Finance • 8 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • last year

Milestone Pharmaceuticals Refreshes Board of Directors

Milestone Pharmaceuticals Inc. – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -... Full story

Yahoo Finance • 2 years ago

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership strengthened with the appointment of Stuart... Full story

Yahoo Finance • 2 years ago

EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases,... Full story

Yahoo Finance • 2 years ago

EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023

WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced... Full story

Yahoo Finance • 2 years ago

EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team

– Stuart Duty appointed to EyePoint’s Board of Directors – – George Elston promoted to Executive Vice President – WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to... Full story

Yahoo Finance • 2 years ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disord... Full story

Yahoo Finance • 2 years ago

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Pla... Full story